Clinical Trial: A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049081) titled 'A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases' on June 20.

Brief Summary: This is a prospective, single-arm, open-label and dose-escalation study to evaluate LUCAR-G79 in adult subjects with relapsed/refractory autoimmune diseases.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Autoimmune Diseases

Intervention: BIOLOGICAL: LUCAR-G79 T cells

Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Nanjing Legend Biotec...